Sign In
Section Navigation
Common TitleSENSE
Official Title A Phase IIb, Multi-centre, Randomised, Double-blind, Active-controlled Trial Comparing the Neuropsychiatric Adverse Event Profile of Etravirine 400mg qd Versus Efavirenz 600mg qd in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in ARV Therapy-naive HIV-1 Infected Subjects
Phase Phase IIB
ClinicalTrials.gov NCT00903682
Treatments
Etravirine
Etravirine Intelence

Etravirine

Tradename:IntelenceOther Names:ETRClass:Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
Categories PharmacologyTreatment-NaiveAdverse Effects
Funding
IndustryJanssen-Cilag
References
  • Fätkenheuer G, Duvivier C, Rieger A, et al. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial. J Antimicrob Chemother. 2012;67:685-90.
    [PubMed Abstract]
  • Gazzard B, Duvivier C, Zagler C, et al. Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results. AIDS. 2011;25:2249-58.
    [PubMed Abstract]
  • Nelson M, Stellbrink HJ, Podzamczer D, et al. A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS. 2011;25:335-40.
    [PubMed Abstract]

Share by e-mail

Since you've received 80% or better on this quiz, you may claim continuing education credit.

You seem to have a popup blocker enabled. If you want to skip this dialog please Always allow popup windows for the online course.